00:00-00:48
Narrator:
Indications
Taltz is indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis, or PsO, who are candidates for systemic therapy or phototherapy. Taltz is also indicated for adults with active psoriatic arthritis, or PsA, for adults with active ankylosing spondylitis, or AS, and for adults with active non-radiographic axial spondyloarthritis, or nr-axSpA, with objective signs of inflammation.
Contraindications
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
Full Important Safety Information is available at the conclusion of the video. Please see Prescribing Information and Medication Guide. See Instructions for Use included with the device.
Caption
INDICATIONS
Taltz is indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. Taltz is also indicated for adults with active psoriatic arthritis (PsA) for adults with active ankylosing spondylitis (AS) and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
SELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
Full Important Safety Information is available at the conclusion of the video. Please see Prescribing Information and Medication Guide. See Instructions for Use included with the device.
00:49-01:00
[Title screen displays]
Caption: Please see Important Safety Information at the end of the video and the link to full Prescribing Information on this website.
Caption: A PLACE FOR TALTZ IN TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
[Photo and bio of Sr. Soung display]
Caption: Dr. Jennifer Soung is a board-certified dermatologist and the director of clinical research at Southern California Dermatology in Santa Ana, CA. Dr. Soung focuses on medical dermatology and clinical research. She has a passion for treating chronic autoimmune skin diseases, diverse skin tones, and increasing healthcare access to populations facing systemic barriers to care. She serves as Clinical Faculty at Harbor University of California, Los Angeles, and is a member of the medical board of the National Psoriasis Foundation.
01:01-01:52
[Dr. Soung appears]
Narrator: Hi, I'm Doctor Jennifer Soung, a dermatologist and clinical researcher at Southern California Dermatology and Clinical Faculty at Harbor UCLA. I'm passionate about treating chronic autoimmune skin diseases, caring for patients with diverse skin tones, and advancing health care where access to care hasn't always been equal. I'm excited to share my experience and what I've learned with you.
[Inset images display next to Dr. Soung]
Narrator: When my patients come in with plaque psoriasis, they're usually looking for a treatment option that brings real relief. They want it to work quickly and last. I've trusted Taltz for over nine years now, starting from when it was first approved to treat moderate to severe plaque psoriasis. I often turn to Taltz for the right patients because it's been a reliable option. In my experience, it often works fast and delivers lasting results, which is exactly what my patients are looking for.
01:53-02:23
[Line graph displays with required footnotes and disclaimers]
Narrator: In UNCOVER-3, patients receiving Taltz achieved a 56% mean percentage improvement in PASI from baseline as early as week 2, with an increase to 92% improvement at week 12, compared to an 11% and 14% improvement, respectively, for patients receiving placebo. At week 264, patients receiving Taltz achieve 97% improvement from baseline and a mean PASI score of 0.7.
02:24-02:59
[Table displays with required footnotes and disclaimers]
Narrator: Another reason that I keep Taltz in mind is because it delivers results for adults across all its approved uses, and it doesn't have a box warning. I always pay close attention to safety, especially things like opportunistic infections, yeast infections, and malignancies. And the data here helps guide those conversations. For me, the combination of clear skin, fast results, and a safety profile I trust is why Taltz remains a go to option.
The full Important Safety Information for Taltz can be found at the end of the video.
03:00-03:18
[Dr. Soung appears]
Narrator: Thanks for watching and listening to why Taltz has been a trusted option for me over the past 9 years. I feel confident it can help the right patients reach their treatment goals. Please continue watching for additional information on the UNCOVER trials, as well as additional important safety information. \
03:19-03:49
[Bar chart displays with required footnotes and disclaimers]
Narrator: The UNCOVER clinical trials were three randomized, double-blind, placebo-controlled registration trials that evaluated the efficacy and safety of Taltz in adults with moderate to severe plaque psoriasis.
The co-primary efficacy endpoints at week 12 are proportion of patients achieving PASI 75 and proportion of patients with sPGA 0,1 with at least a 2-point improvement from baseline.
03:50-04:15
[Bar chart displays with required footnotes and disclaimers. Dr. Soung also appears alongside chart.]
Narrator: At week 12, Taltz demonstrated complete and consistent skin clearance across all three trials. When looking at complete skin clearance, you can see that in UNCOVER-1, -2, and -3, 35%, 40%, and 38% of Taltz patients, respectively, achieved PASI 100 at 12 weeks versus 0%, 1%, and 0% for placebo.
04:16 – 08:25
Narrator:
INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TALTZ (ixekizumab)
Indications
Taltz is indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis, or PsO, who are candidates for systemic therapy or phototherapy. Taltz is also indicated for adults with active psoriatic arthritis, or PsA, for adults with active ankylosing spondylitis, or AS, and for adults with active non-radiographic axial spondyloarthritis, or nr-axSpA, with objective signs of inflammation.
Contraindications
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. Serious infections have occurred. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. In the post-marketing setting, serious bacterial, viral, and fungal opportunistic infections have been reported in patients receiving IL-17 inhibitors, including Taltz. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue Taltz until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Consider anti-TB therapy prior to initiating Taltz in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving Taltz should be monitored closely for signs and symptoms of active TB during and after treatment.
Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.
Eczematous Eruptions
In the postmarketing setting, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma were reported in patients receiving Taltz; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of Taltz. Treatment may need to be discontinued to resolve the eczematous eruption. Some patients with limited psoriasis treatment options were successfully treated for eczema while continuing Taltz.
Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.
Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.
Taltz is available as an 80 mg/mL, 40 mg/0.5mL, 20 mg/0.25mL injection.
Caption:
IMPORTANT SAFETY INFORMATION FOR TALTZ (ixekizumab)
INDICATIONS
Taltz is indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. Taltz is also indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. Serious infections have occurred. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. In the post-marketing setting, serious bacterial, viral, and fungal opportunistic infections have been reported in patients receiving IL-17 inhibitors, including Taltz. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue Taltz until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Consider anti-TB therapy prior to initiating Taltz in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving Taltz should be monitored closely for signs and symptoms of active TB during and after treatment.
Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.
Eczematous Eruptions
In the postmarketing setting, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma were reported in patients receiving Taltz; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of Taltz. Treatment may need to be discontinued to resolve the eczematous eruption. Some patients with limited psoriasis treatment options were successfully treated for eczema while continuing Taltz.
Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.
Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.
Please see Important Safety Information and the link to full Prescribing Information on this website.
Taltz is available as an 80 mg/mL, 40 mg/0.5mL, 20 mg/0.25mL injection.
IX HCP ISI 20AUG2024
08:26-08:39
Caption: Dr. Jennifer Soung is a paid consultant for Eli Lilly and was compensated for her time. She has also served as a speaker, consultant, and/or investigator for AbbVie, Alumis, Aslan, Amgen, Arcutis, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly, Galderma, Incyte, Johnson & Johnson, KoBio Labs, LEO, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, and UCB.
Caption:
REFERENCES
- Data on file. Lilly USA, LLC. DOF-IX-US-0232.
- Taltz. Prescribing Information. Lilly USA, LLC.
- Deodhar A, Blauvelt A, Lebwohl M, et al. Long-term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis Res Ther. 2024;26(49). doi:10.1186/s13075-023-03257-7.
- Sesin C, Gallo G, Gellett AM, et al. Safety of ixekizumab in patients with psoriatic arthritis: an integrated analysis of 4 clinical trials. Presented at European League Against Rheumatism (EULAR) 2021 Virtual Meeting; June 2-5, 2021.
- Schwartzman S, Deodhar A, Combe B, et al. Safety profile of ixekizumab for the treatment of psoriatic arthritis and axial spondyloarthritis up to 3 years: an updated integrated safety analysis. Arthritis Rheumatol. 2021;73 (suppl 10). 2021 ACR Meeting abstract 1893.
- Data on file. Lilly USA, LLC. DOF-IX-US-0183.
08:40-08:49
[Lilly logo displays]
Caption:
Taltz® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Other product/company names mentioned herein are the trademarks of their respective owners.
PP-IX-US-7288 11/2025 ©LILLY USA, LLC 2025. All rights reserved.
